Related Experiment Video

Updated: Sep 29, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

ras Gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas

Jinyoung Yoo1, Sonya Y Park, Robert A Robinson

  • 1Department of Pathology, St Vincent's Hospital, Catholic University, Suwon, Kyungkido, South Korea.

Archives of Pathology & Laboratory Medicine
|September 3, 2002
PubMed
Abstract

Insights

Ras gene mutations are uncommon in gastric adenocarcinomas, with most found in intestinal-type tumors. Enhanced ERK1/2 activity may indicate tumor invasiveness in gastric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Ras gene mutations are implicated in various cancers.
  • Understanding ras gene alterations in gastric adenocarcinoma is crucial for targeted therapies.
  • Signal transduction pathways involving ERK1 and ERK2 play roles in cell proliferation and differentiation.

Purpose of the Study:

  • To investigate the frequency and patterns of ras gene alterations in human gastric adenocarcinomas.
  • To explore the potential relationship between ras gene mutations and ras signal transduction mediators, specifically ERK1 and ERK2.
  • To examine racial and geographic variations in ras gene alterations in gastric cancer.

Main Methods:

  • Genomic DNA from 104 gastric tumors (70 Korean, 34 US) was analyzed for ras mutations using polymerase chain reaction (PCR) and sequencing.
  • Immunohistochemical analysis was performed to detect the expression of ERK1 and ERK2.
  • Statistical analysis was used to assess correlations between ras mutations, ERK1/2 expression, and clinicopathological features.

Main Results:

  • Ras mutations (H-ras or K-ras) were detected in 14% of gastric tumors (13% in Korean, 18% in US patients).
  • The majority of ras mutations (78-100%) occurred in intestinal-type gastric lesions.
  • ERK1 and/or ERK2 overexpression was observed in 65% of samples, but no direct association with ras mutations was found. However, ERK1/2 expression correlated significantly with tumor progression (P =.007).

Conclusions:

  • Ras mutations are relatively infrequent in gastric adenocarcinomas and do not appear to be driven by distinct racial or geographic mechanisms.
  • The higher prevalence of ras mutations in intestinal-type tumors suggests different carcinogenic pathways compared to diffuse-type tumors.
  • Enhanced ERK1/2 activity may be a characteristic feature associated with tumor invasiveness in gastric cancers, independent of ras mutation status.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...